Ventilator-Associated Pneumonia: A Comprehensive Prevention and Management Guideline

Evidence-based guideline for VAP prevention bundles, diagnostic approaches, empiric and targeted antimicrobial therapy, and surveillance in mechanically ventilated patients.

Records
4
Last revised
March 2026
Editorial responsibility
The Clinical Database

Ventilator-associated pneumonia (VAP) is the most common healthcare-associated infection among mechanically ventilated patients in the intensive care unit, affecting an estimated 5 to 40 percent of patients who require mechanical ventilation for more than 48 hours.12 Despite advances in prevention strategies and bundled care approaches, VAP remains a major driver of ICU morbidity, excess length of stay, antibiotic utilization, and healthcare costs. Attributable mortality estimates range from 3 to 17 percent in carefully controlled studies, though crude mortality in patients who develop VAP may exceed 40 to 50 percent due to the severe underlying illness in this population.23

The past two decades have seen a fundamental evolution in how clinicians define, prevent, diagnose, and treat VAP. The introduction of ventilator-associated event (VAE) surveillance by the national healthcare safety surveillance framework has shifted quality reporting from subjective clinical diagnosis to objective, algorithm-driven event detection.4 Simultaneously, large-scale prevention bundle implementation programs have demonstrated that VAP rates can be reduced by 50 to 70 percent when evidence-based bundle components are reliably applied.56 On the treatment side, the 2016 joint guideline from major American thoracic and infectious diseases professional societies redefined the approach to empiric antibiotic selection, emphasizing local antibiogram-driven therapy, risk stratification for multidrug-resistant (MDR) pathogens, and short-course treatment duration.2

This guideline synthesizes recommendations from the major professional society guidelines, consensus statements, surveillance frameworks, and systematic reviews into a single comprehensive reference for intensivists, pulmonologists, infectious disease specialists, infection preventionists, respiratory therapists, and critical care nurses managing mechanically ventilated patients.12345678

Contents:

PartTitleCoverage
Part 1Definitions, Epidemiology, Pathogenesis & Risk FactorsVAP clinical definition; HAP vs VAP distinction; VAE tier system (VAC, IVAC, PVAP); CDC/NHSN surveillance definitions and algorithm; epidemiology (incidence, mortality, cost, ICU days); pathogenesis of aspiration and biofilm; modifiable and non-modifiable risk factors
Part 2Prevention Bundles & Supplemental StrategiesHead-of-bed elevation; daily sedation interruption and SBTs; oral care and chlorhexidine controversy; subglottic secretion drainage; ETT cuff pressure management; closed vs open suctioning; circuit management; early mobility; stress ulcer prophylaxis; DVT prophylaxis; avoidance of intubation (NIV/HFNC); SDD/SOD; silver-coated ETTs; probiotics; kinetic bed therapy
Part 3Diagnosis & Antimicrobial TreatmentClinical suspicion criteria; CPIS scoring table; microbiologic sampling (ETA vs BAL vs mini-BAL thresholds); blood cultures and urinary antigens; biomarkers (procalcitonin, CRP, sTREM-1); empiric antibiotic selection by MDR risk; complete dosing tables with renal adjustments; de-escalation; short-course duration evidence; inhaled antibiotics; treatment failure evaluation
Part 4Specific Pathogens, Surveillance & Quality MetricsMRSA, Pseudomonas, Acinetobacter, ESBL-producing organisms, Stenotrophomonas targeted therapy; VAE vs VAP reporting; NHSN surveillance definitions and algorithm; quality metrics; bundle compliance monitoring; antibiotic stewardship

  1. Klompas M, Branson R, Cawcutt K, et al. “Strategies to prevent ventilator-associated pneumonia, ventilator-associated conditions, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update.” Infect Control Hosp Epidemiol. 2022;43(6):687-713. SHEA/IDSA. DOI: 10.1017/ice.2022.13 ↩︎ ↩︎

  2. Kalil AC, Metersky ML, Klompas M, et al. “Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.” Clin Infect Dis. 2016;63(5):e61-e111. ATS/IDSA. DOI: 10.1093/cid/ciw353 ↩︎ ↩︎ ↩︎ ↩︎

  3. Torres A, Niederman MS, Chastre J, et al. “International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia.” Eur Respir J. 2017;50(3):1700582. ERS/ESICM/ESCMID/ALAT. DOI: 10.1183/13993003.00582-2017 ↩︎ ↩︎

  4. Magill SS, Klompas M, Balk R, et al. “Developing a new, national approach to surveillance for ventilator-associated events.” Crit Care Med. 2013;41(11):2467-2475. CDC/NHSN. DOI: 10.1097/CCM.0b013e3182a262db ↩︎ ↩︎

  5. Klompas M, Branson R, Eichenwald EC, et al. “Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update.” Infect Control Hosp Epidemiol. 2014;35(8):915-936. SHEA/IDSA. DOI: 10.1086/677144 ↩︎ ↩︎

  6. Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T. “Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia.” Jt Comm J Qual Patient Saf. 2005;31(5):243-248. DOI: 10.1016/S1553-7250(05)31031-2 ↩︎ ↩︎

  7. Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. “Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis.” Crit Care Med. 2011;39(8):1985-1991. DOI: 10.1097/CCM.0b013e318218a4d9 ↩︎

  8. Cochrane Acute Respiratory Infections Group. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C. “Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia.” Cochrane Database Syst Rev. 2016;10:CD008367. DOI: 10.1002/14651858.CD008367.pub3 ↩︎

Frequently asked questions

What is ventilator-associated pneumonia?
Ventilator-associated pneumonia (VAP) is the most common healthcare-associated infection among mechanically ventilated ICU patients, affecting an estimated 5 to 40 percent of patients ventilated for more than 48 hours. Attributable mortality is estimated at 3 to 17 percent in carefully controlled studies, though crude mortality in patients who develop VAP may exceed 40 to 50 percent because of severe underlying illness. It is suspected when a ventilated patient develops a new or progressive infiltrate plus clinical features such as fever, abnormal white count, or purulent secretions.
What is the ventilator bundle for VAP prevention?
Current essential practices include head-of-bed elevation to 30-45 degrees, daily sedation interruption paired with spontaneous breathing trials, oral care with tooth brushing, subglottic secretion drainage, endotracheal tube cuff pressure maintained at 20-30 cmH2O, avoiding intubation with NIV or HFNC when possible, early mobility, minimizing duration of ventilation, and avoiding routine circuit changes. Reliable, combined application of these elements has reduced VAP rates by 50 to 70 percent in large implementation programs. Chlorhexidine oral care is no longer recommended for general ICU patients in the 2022 update, though it remains recommended for cardiac surgery.
How long should antibiotics be given for VAP?
The 2016 guidelines strongly recommend 7 days of antibiotic therapy for most patients rather than longer 10-21 day courses. A landmark multicenter trial comparing 8 versus 15 days found equivalent 28-day mortality and clinical cure with more antibiotic-free days. Non-fermenting gram-negative organisms such as Pseudomonas showed higher recurrence with short courses, so 7-14 days individualized by clinical response is advised for those pathogens.

Ventilator-Associated Pneumonia — Part 4: Specific Pathogens, Surveillance & Quality Metrics

Pathogen-directed therapy for MRSA, Pseudomonas aeruginosa, Acinetobacter baumannii, ESBL-producing Enterobacterales, and Stenotrophomonas maltophilia with dosing tables, VAE versus traditional VAP surveillance reporting, NHSN definitions and algorithms, quality metrics including VAE rates and bundle compliance, and antibiotic stewardship considerations.

guidelines•Mar 2026•guidelines

Ventilator-Associated Pneumonia — Part 3: Diagnosis & Antimicrobial Treatment

Clinical diagnostic criteria, CPIS scoring table, microbiologic sampling strategies (ETA, BAL, mini-BAL) with quantitative thresholds, biomarker guidance, empiric antibiotic selection stratified by MDR risk with complete dosing tables and renal adjustments, de-escalation principles, short-course duration evidence, inhaled antibiotics, and treatment failure evaluation.

guidelines•Mar 2026•guidelines

Ventilator-Associated Pneumonia — Part 2: Prevention Bundles & Supplemental Strategies

Comprehensive evidence review of VAP prevention bundle components including head-of-bed elevation, sedation management, oral care and chlorhexidine controversy, subglottic secretion drainage, ETT cuff pressure, suctioning, circuit management, early mobility, stress ulcer prophylaxis, and supplemental strategies including SDD/SOD, silver-coated ETTs, and probiotics.

guidelines•Mar 2026•guidelines

Ventilator-Associated Pneumonia — Part 1: Definitions, Epidemiology, Pathogenesis & Risk Factors

Clinical and surveillance definitions of VAP, the VAE tier system (VAC, IVAC, PVAP), HAP versus VAP distinction, epidemiology including incidence and mortality data, pathogenesis of aspiration and biofilm formation, and modifiable and non-modifiable risk factors.

guidelines•Mar 2026•guidelines